Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO, March 23, 2022 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the first patient enrolled to…


Previous articleCOMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
Next articleCybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants